Bahar Bastani, MD
Nephrology · St Louis, MONPI 1326059957
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $53,290 of the $87,262 with a category attached, or 61.1%. 15 manufacturers reported payments, led by Travere Therapeutics, Inc. at 55.9% of the total. Reporting peaked in 2023 at $37,810 and has fallen 74.9% since, to $9,503 in 2025. Among nephrology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 165 payments — averaging $528.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$49K
- Amgen$22K
- Alnylam Pharmaceuticals Inc.$11K
- Calliditas Therapeutics US Inc.$5K
- Mallinckrodt Hospital Products Inc.$549
- Otsuka America Pharmaceutical, Inc.$234
- plus $702 from 9 others
What the payments were for
- Consulting fees$13,13015%
- Speaking & faculty fees$53,29061%
- Travel & lodging$14,99317%
- Food & beverage$5,5856%
- Education$2640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 104 | $48,739 |
| Amgen(2 entities) | 31 | $21,694 |
| Alnylam Pharmaceuticals Inc. | 4 | $10,589 |
| Calliditas Therapeutics US Inc. | 8 | $4,755 |
| Mallinckrodt Hospital Products Inc. | 6 | $549 |
| Otsuka America Pharmaceutical, Inc. | 2 | $234 |
| Novo Nordisk | 2 | $142 |
| Sanofi | 1 | $125 |
| Novo Nordisk Health Care AG | 1 | $123 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $116 |
| Aurinia Pharma U.S., Inc. | 1 | $90 |
| GSK | 1 | $36 |
| Lundbeck LLC | 1 | $31 |
| Vifor Pharma, Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$87,262 in reported general payments places this provider in the 95th percentile of 253 nephrology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Everolimus | 12 | $152,854 |
| Thiola EcTiopronin | 12 | $91,577 |
| LokelmaSodium Zirconium Cyclosilicate | 14 | $19,935 |
| Cinacalcet Hcl | 51 | $17,168 |
| JardianceEmpagliflozin | 24 | $15,495 |
| EliquisApixaban | 24 | $13,666 |
| FarxigaDapagliflozin Propanediol | 20 | $12,619 |
| Envarsus XrTacrolimus | 27 | $11,022 |
| Tacrolimus | 26 | $6,003 |
| Icosapent Ethyl | 34 | $5,645 |
| VascepaIcosapent Ethyl | 15 | $5,132 |
| Calcitriol | 259 | $3,575 |
| Cyclosporine ModifiedCyclosporine, Modified | 26 | $3,178 |
| Potassium Citrate ErPotassium Citrate | 39 | $2,887 |
| Mycophenolate Mofetil | 32 | $2,874 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $19 | $15,49524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 253 nephrology providers in Missouri.
Other nephrology in St Louis
- Kevin MartinSt Louis$189K
- Nicholas GourtzelisSt Louis$9K
- Derek LarsonCreve Coeur$605K
- Marcos RothsteinSaint Louis$350K
- Anuja JavaSaint Louis$240K
- Alejandro AlvarezFlorissant$176K
- Gary SingerSaint Peters$170K
- Daniel CoyneSaint Louis$163K
- Tarek AlhamadSaint Louis$155K
- Tingting LiSaint Louis$130K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.